Abstract:
:We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in the Netherlands over a 26 year period. ALL patients <18 years were selected from the Netherlands Cancer Registry and the Dutch Childhood Oncology Group. Trend analyses were performed over time and by age group and ALL subtype. Between 1990 and 2015, 2997 ALL patients were diagnosed, i.e. 115 patients (range 87-147) per year. Overall incidence remained stable at 37 per million children, despite increases for B-cell precursor ALL (BCP-ALL) at age 10-14 years (AAPC + 1.4%, p = 0.04) and T-cell ALL at 15-17 years (AAPC + 3.7%, p = 0.01). Five-year survival increased from 80% in 1990-94 to 91% in 2010-15 (p < 0.01). Mortality decreased by 4% annually (p < 0.01). Patients 15-17 years were increasingly treated in a paediatric oncology centre, from 35% in 1990-94 to 87% in 2010-15 and experienced a 70% reduction of risk of death compared to those treated outside such a centre (p < 0.01). Significant progress against childhood ALL has been made in the Netherlands, visible by improved survival rates coinciding with declining mortality rates. These outcomes were accompanied by stable incidence rates, despite increases for BCP-ALL at age 10-14 years and T-cell ALL at age 15-17 years.
journal_name
Leukemiajournal_title
Leukemiaauthors
Reedijk AMJ,Coebergh JWW,de Groot-Kruseman HA,van der Sluis IM,Kremer LC,Karim-Kos HE,Pieters Rdoi
10.1038/s41375-020-01024-0subject
Has Abstractpub_date
2020-08-21 00:00:00eissn
0887-6924issn
1476-5551pii
10.1038/s41375-020-01024-0pub_type
杂志文章相关文献
LEUKEMIA文献大全abstract::Detection of minimal residual disease (MRD) is the most sensitive method to evaluate treatment response and one of the strongest predictors of outcome in childhood acute lymphoblastic leukemia (ALL). The 10-year update on the I-BFM-SG MRD study 91 demonstrates stable results (event-free survival), that is, standard ri...
journal_title:Leukemia
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1038/leu.2008.5
更新日期:2008-04-01 00:00:00
abstract::The BCL-2 inhibitor venetoclax has only limited activity in DLBCL despite frequent BCL-2 overexpression. Since constitutive activation of the B cell receptor (BCR) pathway has been reported in both ABC and GCB DLBCL, we investigated whether targeting SYK or BTK will increase sensitivity of DLBCL cells to venetoclax. W...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-019-0442-8
更新日期:2019-10-01 00:00:00
abstract::The study was designed to compare clofarabine plus daunorubicin vs daunorubicin/ara-C in older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Eight hundred and six untreated patients in the UK NCRI AML16 trial with AML/high-risk MDS (median age, 67 years; range 56-84) and norm...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2016.225
更新日期:2017-02-01 00:00:00
abstract::Multiple myeloma (MM) is the second most common blood malignancy. Epidemiological family studies going back to the 1920s have provided evidence for familial aggregation, suggesting a subset of cases have an inherited genetic background. Recently, studies aimed at explaining this phenomenon have begun to provide direct...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/s41375-019-0703-6
更新日期:2020-03-01 00:00:00
abstract::In vitro enzymatic amplification and direct sequencing were used to detect and characterize t(14;18) recombination junctions in peripheral blood and bone marrow mononuclear cell preparations from patients with follicular lymphoma in remission. Samples from 24/44 patients were found to be positive for translocations in...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1991-07-01 00:00:00
abstract::Acute myeloid leukemia (AML) with minimal differentiation was usually referred to as acute undifferentiated leukemia in the past. With the help of immunophenotyping, this subtype of leukemia was shown to express myeloid antigens on the blasts and was designated AML-M0 by FAB Cooperative Study Group in 1991. Among the ...
journal_title:Leukemia
pub_type: 临床试验,杂志文章
doi:10.1038/sj.leu.2401521
更新日期:1999-10-01 00:00:00
abstract::The aim of this study was to collect prospectively unselected, population-based data on young adults with acute myeloid leukaemia (AML) over a 9-year period and to evaluate the impact on survival of the introduction of allogeneic transplantation performed in first remission. The population within the Northern Region o...
journal_title:Leukemia
pub_type: 临床试验,杂志文章
doi:
更新日期:1995-07-01 00:00:00
abstract::Adult BL/6 mice are highly sensitive to lymphomagnesis by the radiation leukemia virus variant A-RadLV (80-100% T-cell lymphoma incidence after a latency of 70-110 days). This study shows that the in vivo elimination of T-cell subsets (including suppressor and cytotoxic T-cells) achieved by the repeated administration...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1991-06-01 00:00:00
abstract::Recurrent chromosomal rearrangements are observed in many leukemia subtypes. Recently, it has been shown that several of these translocations/inversions were associated with the loss of sequences located in the vicinity of the chromosomal breakpoints. So far, such deletions have not been described for the t(8;21) tran...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402585
更新日期:2002-09-01 00:00:00
abstract::All-trans-retinoic (ATRA) treatment of patients with acute promyelocytic leukemia results in differentiation of the malignant cells and a high complete remission rate. ATRA treatment induced granulocytic differentiation in HL-60 cells as assessed by nitroblue tetrazolium (NBT) reduction, but had no effect on non-speci...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1993-03-01 00:00:00
abstract::The current study was undertaken to search for differences in the biology of cytogenetic subgroups in patients with de novo acute myeloid leukemia (AML). In addition, factors influencing the metabolism of cytosine arabinoside (araC) as the key agent of antileukemic activity were assessed. Bone marrow aspirates from 91...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402029
更新日期:2001-03-01 00:00:00
abstract::Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-caten...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-018-0334-3
更新日期:2019-06-01 00:00:00
abstract::The transcription factor CCAAT enhancer-binding protein alpha (C/EBPalpha) has an important role in granulopoiesis. The tumor suppressor function of C/EBPalpha is shown by the findings that loss of expression or function of C/EBPalpha in leukemic blasts contributes to a block in myeloid cell differentiation and to leu...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2010.37
更新日期:2010-05-01 00:00:00
abstract::The activation of natural killer (NK) cells leads to degranulation and secretion of cytotoxic granula. During this process, the lytic granule membrane protein CD107a becomes detectable at the cell surface. Based on this phenomenon, we have analyzed by a novel flow cytometry-based assay, the number and phenotype of NK ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403704
更新日期:2005-05-01 00:00:00
abstract::To determine the frequency and prognostic significance of recently described genetic lesions in pediatric acute lymphoblastic leukemia (ALL), all cases with available leukemic cell samples treated on St Jude Study XII were analyzed by molecular techniques for alterations of the p16, MLL and ETV6 genes. Homozygous p16 ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2400779
更新日期:1997-08-01 00:00:00
abstract::CDCP1, a novel stem cell marker, is expressed in hematopoietic cell line K562 but not in Jurkat. When CDCP1 promoter was transfected exogenously, Jurkat showed comparable promoter activity with K562, suggesting that the factor to enhance transcription was present but interfered to function in Jurkat. The reporter assa...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2404312
更新日期:2006-09-01 00:00:00
abstract::The in vitro effects of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR, fenretinide) on primary B-cell chronic lymphocytic leukemia (CLL) cells from previously untreated CLL patients were investigated. 4HPR promoted the intrinsic apoptotic pathway by reactive oxygen species (ROS) generation and was accompa...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2012.98
更新日期:2012-10-01 00:00:00
abstract::Monoclonal antibody (mAb) M195 is a mouse IgG2a reactive with a myelomonocytic differentiation antigen found on early myeloid cells and monocytes. The reactivity of M195 with fresh hematopoietic neoplasms in the blood or bone marrow from 227 patients at Memorial Hospital was determined by flow cytometry. M195 was posi...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1989-06-01 00:00:00
abstract::Human leukocyte antigens (HLA) class I molecules restrict the interaction between cytotoxic T cells and target cells. Abnormalities in HLA class I antigen expression and/or function may provide tumor cells with a mechanism for escaping immune surveillance and resisting T cell-based immunotherapies. The potential for a...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401982
更新日期:2001-01-01 00:00:00
abstract::Although reciprocal chromosomal translocations are not typical for B-cell chronic lymphocytic leukemia (B-CLL), we identified the novel t(1;6)(p35.3;p25.2) in eight patients with this disorder. Interestingly, all cases showed lack of somatically mutated IgV(H). Clinical, morphological, immunologic, and genetic feature...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403543
更新日期:2005-01-01 00:00:00
abstract::Engagement of NKG2D by their ligands (NKG2D-L), as the human major histocompatibility complex class I-related molecules MIC-A and the UL16-binding proteins, on cytolytic lymphocytes leads to the enhancement of antitumour effector functions. These ligands are missing or expressed at very low levels on leukaemic cells; ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2008.354
更新日期:2009-04-01 00:00:00
abstract::A 32-year-old white woman was admitted with a diagnosis of T lymphoblastic lymphoma and a bone marrow and peripheral blood cytology that was suggestive of a myeloproliferative syndrome (MPS). In addition, islets of myeloid precursors were found in the lymph node where the lymphoma had been diagnosed. Cytogenetic exami...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1995-06-01 00:00:00
abstract::Various clinical and laboratory observations suggest that the leukaemia cells in chronic myeloid leukaemia (CML) are potentially immunogenic. Whilst the ability of the leukaemia cells to elicit an anti-leukaemic immune response in the allogeneic setting is established, it remains unclear why such anti-leukaemic respon...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2400858
更新日期:1997-12-01 00:00:00
abstract::Currently available data on chimeric antigen receptor (CAR)-T cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated multiple myeloma (MM) patients. The CAR-T field in MM is rapidly evolving with >50 currently ongoing clinical trials across all phases, different CAR-T design, or targets. ...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/s41375-020-0930-x
更新日期:2020-09-01 00:00:00
abstract::Acute promyelocytic leukemia (APL) cells express different types of procoagulant activity (PCA), including tissue factor (TF), and cancer procoagulant (CP). The aim of this study was to investigate whether the NB4 cell line, the first ever isolated human APL line, with the typical t(15;17) chromosomal balance transloc...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1994-01-01 00:00:00
abstract::The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20-30% blasts treated by AZA, that is disease categories wherein this drug is approved by Food and Drug Administration (FDA...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2011.71
更新日期:2011-07-01 00:00:00
abstract::Bortezomib is a potent drug for the treatment of multiple myeloma. Its anti-tumor activity is mediated by proteasome inhibition leading to decreased cell proliferation and induction of apoptosis. However, an unimpaired proteasomal function plays a crucial role for the induction of anti-tumor immunity by dendritic cell...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2404734
更新日期:2007-07-01 00:00:00
abstract::Fas ligand (FasL) is capable of inducing apoptosis of lymphoid cells by cross-linking with its natural receptor, Fas. We aimed to investigate the possible role of the Fas/FasL-mediated apoptosis in the development of human lymphomas. FasL mRNA was detected by reverse transcriptase-polymerase chain reaction in 38 out o...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2400815
更新日期:1997-11-01 00:00:00
abstract::The notion that inherited predisposition contributes to the development of haematological malignancies is generally thought of as being a relatively new idea. However, Videbaek made a clear enunciation of such a hypothesis in 1947, from a study of tumour incidence in relatives of patients with different leukaemias. To...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403727
更新日期:2005-06-01 00:00:00
abstract::Targeting of B cell receptor associated kinases (BAKs), such as Bruton's tyrosine kinase (BTK) or phosphoinositol-3-kinase (PI3K) delta, by specific inhibitors has revolutionized the therapy of B lymphoid malignancies. BAKs are critical signaling transducers of BCR signaling and seem relevant in B cell lymphoma pathog...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/s41375-018-0366-8
更新日期:2019-03-01 00:00:00